Dry mouth as a novel indicator of hoarseness caused by inhalation therapy

References

• Dalby R, Suman J. Inhalation therapy: technological milestones in asthma treatment. Adv Drug Deliv Rev 2003;55:779–791
   PubMed Web of Science ®Google Scholar
• Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD002991
   PubMed Web of Science ®Google Scholar
• Kajiwara A, Kita A, Saruwatari J, Morita K, Oniki K, Yamamura M, Murase M, et al. Absence of gargling affects topical adverse symptoms caused by inhaled corticosteroids in females. J Asthma 2014;51:221–224
   Web of Science ®Google Scholar
• Barnes NC. The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J 2007;16:149–154
   PubMedGoogle Scholar
• Fabbri L, Burge PS, Croonenborgh L, Warlies F, Weeke B, Ciaccia A, Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax 1993;48:817–823
   PubMed Web of Science ®Google Scholar
• Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol 2007;98:225–238
   PubMed Web of Science ®Google Scholar
• Ishizuka T, Hisada T, Aoki H, Yanagitani N, Kaira K, Utsugi M, Shimizu Y, et al. Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma. Allergy Asthma Proc 2007;28:550–556
   PubMedGoogle Scholar
• Ayres JG, Bateman ED, Lundbäck B, Harris TA. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group. Eur Respir J 1995;8:579–586
   PubMed Web of Science ®Google Scholar
• Frois C, Wu EQ, Ray S, Colice GL. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther 2009;31:2779–2803
   PubMed Web of Science ®Google Scholar
• Galván CA, Guarderas JC. Practical considerations for dysphonia caused by inhaled corticosteroids. Mayo Clin Proc 2012;87:901–904
   PubMed Web of Science ®Google Scholar
• Gerdin EW, Einarson S, Jonsson M, Aronsson K, Johansson I. Impact of dry mouth conditions on oral health-related quality of life in older people. Gerodontology 2005;22:219–226
   PubMedGoogle Scholar
• Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 2007;96:644–647
   PubMed Web of Science ®Google Scholar
• Molimard M, Le Gros V, Robinson P, Bourdeix I. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting. J Aerosol Med Pulm Drug Deliv 2010;23:91–95
   PubMed Web of Science ®Google Scholar
• Lux R, Awa W, Walter U. An interdisciplinary analysis of sex and gender in relation to the pathogenesis of bronchial asthma. Respir Med 2009;103:637–649
   Google Scholar
• Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215–228
   PubMed Web of Science ®Google Scholar
• Adams N, Lasserson TJ, Cates CJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007:CD002310
   Google Scholar
• Gallivan GJ, Gallivan KH, Gallivan HK. Inhaled corticosteroids: hazardous effects on voice-an update. J Voice 2007;21:101–111
   PubMed Web of Science ®Google Scholar
• Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth, 2nd ed. Gerodontology 1997;14:33–47
   PubMedGoogle Scholar
• Hira D, Okuda T, Kito D, Ishizeki K, Okada T, Okamoto H. Inhalation performance of physically mixed dry powders evaluated with a simple simulator for human inspiratory flow patterns. Pharm Res 2010;27:2131–2140
   PubMed Web of Science ®Google Scholar
• Yakubu SI, Assi KH, Chrystyn H. Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: the influence of flow and volume. Int J Pharm 2013;455:213–218
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Klug B, Sumby BS, Burnell PK. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998;11:1111–1115
   PubMed Web of Science ®Google Scholar
• Hira D, Okuda T, Ichihashi M, Mizutani A, Ishizeki K, Okada T, Okamoto H. Influence of peak inspiratory flow rates and pressure drops on inhalation performance of dry powder inhalers. Chem Pharm Bull (Tokyo) 2012;60:341–347
   PubMed Web of Science ®Google Scholar
• Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers – implications for in vitro testing. J Aerosol Med 1993;6:99–110
   PubMedGoogle Scholar